Evidence map›Paper›PMID 19544439›Full record

ArticleStem cells (Dayton, Ohio)2009

Noninvasive bioluminescent imaging demonstrates long-term multilineage engraftment of ex vivo-expanded CD34-selected umbilical cord blood cells.

David Steiner, Juri Gelovani, Barbara Savoldo, Simon N Robinson, William K Decker, Nathalie Brouard, Amer Najjar, Dongxia Xing, Hong Yang, Sufang Li and 6 more

Abstract read
In one paragraph

Article in Stem cells (Dayton, Ohio), 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
1.4field-weighted citation impact, top 18% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 18 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Inducible Caspase-9 Selectively Modulates the Toxicities of CD19-Specific Chimeric Antigen Receptor-Modified T Cells.Molecular therapy : the journal of the American Society of Gene Therapy · 2017
    Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 1 country.

David SteinerDepartment of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
Juri Gelovani
Barbara Savoldo
Simon N Robinson
William K Decker
Nathalie Brouard
Amer Najjar
Dongxia Xing
Hong Yang
Sufang Li
Frank Marini
Patrick A Zweidler-McKay
Catherine M Bollard
Elizabeth J Shpall
Gianpietro Dotti
Paul J Simmons
The University of Texas MD Anderson Cancer Center · USBaylor College of Medicine · USBrown Foundation · USThe University of Texas Health Science Center at Houston · US

Funding

Hematopoietic Progenitor Cells- Cord BloodR01CA061508 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI REZVANI, KATY, SHPALL, ELIZABETH J · 1993 to 2020
$5.1M
NCI NIH HHS 5 R01 CA061508-13NCI NIH HHS R01 CA061508
6 · The paper itself

Abstract

The use of umbilical cord blood (UCB) grafts for hematopoietic stem cell transplantation (HSCT) is a promising technique that permits a degree of human leukocyte antigen mismatch between the graft and the host without the concomitant higher rate of graft-versus-host disease that would be observed between an adult marrow graft and a mismatched host. A disadvantage to the use of UCB for HSCT is that immune reconstitution may be significantly delayed because of the low stem cell dose available in the graft. Ex vivo expansion of UCB CD34 cells would provide a greater number of stem cells; however, there are persistent concerns that ex vivo-expanded CD34 cells may lose pluripotency and the ability to contribute meaningfully to long-term engraftment. To address this issue, we transduced CD34-selected UCB cells with a lentiviral construct expressing luciferase, and determined homing and engraftment patterns in vivo by noninvasive bioluminescent imaging in sublethally irradiated NOD/SCID/IL-2Rgamma(-/-) (NSG) mice. Graft contribution to multilineage commitment was also confirmed by analysis of primary and secondary transplants by flow cytometry and immunohistochemistry. Our results demonstrate that, other than a mild delay at the onset of engraftment, there were no significant differences in lineage repopulation or in long-term or secondary engraftment between culture-expanded and unexpanded UCB CD34-selected cells. The results suggest that multipotent stem cells can be expanded ex vivo and can contribute meaningfully to long-term hematopoietic engraftment.

Indexed as

AnimalsAntigens, CD34Cell LineageCord Blood Stem Cell TransplantationFetal BloodFlow CytometryHumansImmunohistochemistryLuciferases, FireflyLuminescent AgentsLuminescent MeasurementsMesenchymal Stem CellsMiceMice, Inbred NODMice, SCIDTransduction, GeneticAntigens, CD34Luciferases, FireflyLuminescent Agents

Identifiers

PMID19544439
PMCPMC3348864
OpenAlexW2088855571

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.